About Dermavant
Dermavant is a Healthcare company based in Phoenix (United States) founded in 2016, and was acquired by Organon in September 2024. Small molecule therapeutics for inflammatory skin diseases are developed. Dermavant has raised $160 million across 2 funding rounds from investors including Marathon Asset Management, NovaQuest Capital Management and Organon. Its chief executive, as recorded, is Todd Zavodnick. Dermavant offers products and services including VTAMA Cream. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its legal entity is Dermavant Sciences, Inc. Its competitors include Revance Therapeutics, Castle Creek Pharma and Sol-Gel Technologies; 3 of its 3 listed competitors have raised funding.
Company details
Dermavant was founded in 2016 and is headquartered in Phoenix, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics are developed for inflammatory skin conditions. The lead candidate, DMVT-505, targets psoriasis and atopic dermatitis by modulating AhR and inhibiting proinflammatory factors. Additional products include DMVT-502, in Phase 1 trials for atopic dermatitis and vitiligo, and DMVT-504 for primary focal hyperhidrosis.
- Headquarters Phoenix, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website dermavant.com
- Social LinkedIn X Facebook
- Acquired by Organon (Sep 2024)
- Legal Name Dermavant Sciences, Inc.
- Total Equity Funding$160M (USD)
in 2 rounds
- Latest Funding Round$160M (USD), Series D
Jun 2021
- InvestorsMarathon Asset Management
& 2 more
- Acquired byOrganon
(Sep 2024)
Products & Services of Dermavant
Dermavant offers a comprehensive portfolio of products and services, including VTAMA Cream.
Cream for treating chronic skin conditions like psoriasis.
Funding Insights of Dermavant
Dermavant has successfully raised a total of $160M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $160 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $160M
- Total Rounds 2
- Last Round Series D — $160M
- First Round $40M
(Jun 2021)
- Investors Count 2
All 2 funding rounds of Dermavant with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $40M | Debt – Conventional | – | – | – |
| Jun 2021 | $160M | Series D | – | Marathon Asset Management, NovaQuest Capital Management | – |
3 investors in total: 3 institutional.
Investors in Dermavant
Dermavant has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Marathon Asset Management, NovaQuest Capital Management and Organon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm focused on life science and healthcare companies | novaquest.com | Raleigh, United States | ||
Diversified investment management services are provided across asset classes. | 1998 | marathonfund.com | New York, United States | |
Organon is focused on improving women's health globally. | organon.com | Jersey City, United States |
Investor details for Dermavant
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dermavant
338 people are tracked at Dermavant (207 in leadership, 10 in board & advisors, 121 in team).
| Name | Role | Group |
|---|---|---|
Todd Zavodnick | CEO | Leadership |
Damien Morris | Associate Director Of Finance External Manufacturing | Leadership |
Charlotte Owens | Head of Medical Affairs & Outcomes Research | Leadership |
Sara Dean | Global Director, Medical Affairs - Contraception Strategy | Leadership |
Mostafa Taha | Global Director Commercial Trade Channels | Leadership |
Eddie Yu | Director, Finance - Above Market Accounting | Leadership |
Leanne Miller | Associate Director, Customer Experience & Commercial Acceleration | Leadership |
Sadia Khan | Director Fp&a And Strategy | Leadership |
Nadim Hawwari | SCM & Integration Finance Associate Director | Leadership |
Therry Engelen | Associate Director / Operations Lead | Leadership |
Wayne Chen | Executive Director, Translational Medicine And Early Clinical Development Lead | Leadership |
Julie Pentz | Chief Procurement Officer | Leadership |
Rijesh Shrestha | Director, Transfer Pricing | Leadership |
Glenn Coleman | Associate Director, Business Technology Processes & Governance | Leadership |
Rachel Stahler | Chief Digital & Growth Officer | Leadership |
Subhajit Singha | Associate Director - Enterprise Data & Analytics Platform | Leadership |
Sloan Tandet | Associate Director, Market Research Global Commercial Insights & Analytics | Leadership |
Samantha Bruno | Director | Leadership |
Wendy Wocher | Associate Director Business/tech. Analysis | Leadership |
Julia Luftmann | Associate Director, Compliance & Operations - Global Business Insights And Analytics | Leadership |
318 more people are available in the full profile.
Complete people profiles for Dermavant
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Dermavant
3 dated milestones of Dermavant across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Dermavant is founded.
- Funding First funding round of $40.0M.
- Exit Acquired by Organon.
Competitors of Dermavant
Dermavant has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Castle Creek Pharma and Sol-Gel Technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| sol-gel.com | 1998 | United States | $9M | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. |
Detailed competitors of Dermavant
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dermavant
Websites that share an audience with Dermavant (dermavant.com).
Websites whose visitors overlap most with Dermavant. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alkermes.com | 100% | 22.7K | #1,117,011 | View details | |
| organon.com | 77% | #267,781 | View details | ||
| abbvie.com | 76% | 851.9K | #69,141 | View details | |
| pfizer.com | 76% | 1.9M | #24,984 | View details |
Top companies in Dermatology
3 companies that operate in the same segment as Dermavant (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dermavant
Complete news archive for Dermavant
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dermavant
Dermavant was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Dermavant is headquartered in Phoenix, United States. It is registered at Phoenix, Arizona, United States.
Todd Zavodnick is the CEO of Dermavant, as recorded in our data.
Dermavant is a funded company, having raised a total of $160M across 2 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $40M, raised on Jun 2021.
Dermavant was founded in 2016 and is headquartered in Phoenix, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics are developed for inflammatory skin conditions. The lead candidate, DMVT-505, targets psoriasis and atopic dermatitis by modulating AhR and inhibiting proinflammatory factors. Additional products include DMVT-502, in Phase 1 trials for atopic dermatitis and vitiligo, and DMVT-504 for primary focal hyperhidrosis.
Dermavant's top competitors include Revance Therapeutics, Sol-Gel Technologies and Castle Creek Pharma.
Dermavant offers VTAMA Cream.
Dermavant has 3 investors. Key investors include Marathon Asset Management, NovaQuest Capital Management, and Organon.
Dermavant operates through Dermavant Sciences, Inc..
Yes. Dermavant was acquired by Organon in September 2024.